Wikisage, the free encyclopedia of the second generation, is digital heritage
Rufinamide: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
m (hide url) |
||
| Line 1: | Line 1: | ||
[[Lennox-Gastaut syndrome|Lennox-Gastaut]] is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconcluside | [[Lennox-Gastaut syndrome|Lennox-Gastaut]] is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconcluside | ||
Otsuka et al (2014) state efficacious and well tolerated AED | Otsuka et al (2014) state efficacious and well tolerated AED | ||
<ref>[http://www.epires-journal.com/article/S0920-1211(14)00228-9/pdf | <ref>[http://www.epires-journal.com/article/S0920-1211(14)00228-9/pdf Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan]</ref>(cf. Alssad et Coren 2014) <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256616/pdf/bcp0078-1264.pdf Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials] </ref> | ||
Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan]</ref>(cf. Alssad et Coren 2014) <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256616/pdf/bcp0078-1264.pdf Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials] </ref> | |||
<small>"Rufinamide received the status of orphan drug for [[epilepsy]] in 2004 in Europe"</small> | <small>"Rufinamide received the status of orphan drug for [[epilepsy]] in 2004 in Europe"</small> | ||
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12689/epdf | <ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12689/epdf Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience]</ref> | ||
Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience]</ref> | |||
<references/> | <references/> | ||
Revision as of 23:25, 27 January 2016
Lennox-Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconcluside Otsuka et al (2014) state efficacious and well tolerated AED [1](cf. Alssad et Coren 2014) [2]
"Rufinamide received the status of orphan drug for epilepsy in 2004 in Europe"
[3]
- ↑ Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan
- ↑ Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials
- ↑ Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience
